The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

Approval was based on the pivotal Phase 3 CodeBreaK 300 study.

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Sotorasib is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Amgen Inc (Symbol: AMGN) entered into oversold territory, hitting an RSI reading of 29.7 ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ... The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated ...